Prostate Cancer

Dr. Pandey is a nuclear radiology researcher working with a team to develop a new radioactive tracer to detect prostate cancer.

By Suzanne Ferguson • September 5, 2019

Genetic alterations in low-risk prostate cancer diagnosed by needle biopsy can identify men that harbor higher-risk cancer in their prostate glands, Mayo Clinic has discovered.

By Mayo Clinic News Network • January 15, 2019

This week’s Research Roundup highlights the development and validation of a prostate cancer genomic signature that predicts early androgen deprivation therapy (ADT) treatment response following radical prostatectomy.

By Kelley Luedke • May 21, 2018

This week’s Research Roundup highlights how the loss of FOXO1 cooperates with TMPRSS2-ERG overexpression to promote prostate tumorigenesis and cell invasion.

By Kelley Luedke • January 15, 2018

This week’s Research Roundup highlights individual patient-level meta-analysis of the performance of the Decipher genomic classifier in high-risk men after prostatectomy to predict development of metastatic disease.

By Kelley Luedke • September 4, 2017

This week’s Research Roundup highlights how intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation.

By Kelley Luedke • August 21, 2017

In this month’s “Hot Topic,” Alicia Algeciras-Schimnich, Ph.D., will provide you with valuable information regarding the utility of the prostate specific antigen test, and how the calculation of a prostate health index, or phi, can help to stratify a patient’s risk for prostate cancer and reduce unnecessary biopsies.

By Alicia Algeciras-Schimnich • August 14, 2017

The prostate health index or phi test reduces the need for prostate cancer biopsies by 30 percent.

By Gina Chiri-Osmond • July 28, 2017

This week’s Research Roundup highlights how the androgen receptor variant AR-V9 is co-expressed with AR-V7 in prostate cancer metastases and predicts abiraterone resistance.

By Kelley Luedke • May 15, 2017

Video Overview Clinical Information Specimen Performance Useful For Assessing the patient’s probability of having detectable prostate cancer when total prostate specific antigen (PSA) concentrations are between 4–10 ng/mL. Results from a prospective, multicenter clinical trial found that phi provides better risk stratification and reduces unnecessary biopsies by 30%, which reduces medical costs and time for the patient.1 View in Test Catalog Video [...]

By Mayo Clinic Laboratories • May 9, 2017